DanCann Pharma A/S named "Entrepreneur of the Year 2021" in Varde Municipality

COPENHAGEN, Denmark, 17 March 2022 – DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”), hereby announce that the Company has been named Entrepreneur of the year 2021 in Varde municipality.

On 16 March 2022 the business association ProVarde held its annual award event. In the category “The Entrepreneurship Company of the Year 2021” DanCann Pharma won first prize.

Jeppe Krog Rasmussen, CEO of DanCann Pharma comments:

- At DanCann Pharma, we clearly notice that support for entrepreneurship has a high priority in Varde Municipality, and this has clearly been a contributing factor to the Company, which we have built up with support from colleagues, forces in the local area, partners, entrepreneurs, and investors.

At the award ceremony, Finn Erik Kristiansen, director of ProVarde, justified the choice of DanCann Pharma as the Entrepreneur of the Year by saying that DanCann Pharma is an excellent example of a knowledge company that has understood to take advantage of new opportunities in legislation to make a difference for people who need help.

Jeppe Krog Rasmussen:

- We are proud that we have been considered for the great prize in general - and it is an big honor for us that we have won it. We would like to appear as a significant asset for Varde Municipality and help give Ansager a new profile by contributing with commitment and dynamics to the local area. At the same time, it is important for us to show that it is possible to establish and run a high-tech company, even if it is at some distance from the main road.

Disclaimer

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.
For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com